PPT-Statin Landmark Trials Across the Spectrum of Risk: Seconda

TNT Study Design Treating to New Targets 2 5 years 10001 Patients Clinically evident CHD LDLC 130 250 mgdL following up to 8week washout and 8week openlabel runin with atorvastatin. Louis H. Stein, Jessica Berger, Maryann . Tranquilli. , . John A. . Elefteriades. .. . The Aortic Institute at Yale – New Haven Hospital . Bench top to bedside interaction. . Medial Degeneration . College. Counselor visit April 2015. Fast Facts. Located in rural . Putney,VT. and minutes from Brattleboro, VT. Small college with 480 students. Over 80 faculty, 6:1 ratio. College exclusively serves students with language based learning disabilities (including dyslexia), ADHD, and autism spectrum disorders (ASD).. IB T-Mobile Benchmark. Dec, 2012. Landmark Medical Center. N. Landmark Medical Center IB baseline. GSM Summary. 2. 1. G. 4. 3. Landmark Medical Center IB baseline. UMTS Summary. G. 1. 2. 4. 3. Landmark Medical Center IB baseline. Step 2 – Research your city or landmark!. . Find information that would . . encourage people to visit! You. . must include the following: . . . Copies application data from one environment to another. Application data. Security. User data. Refresh test from production. Upgrade to newer version. Can’t I just copy like LSF?. LSF Productline Copy. Under-Representation of Women . in Clinical Trials. CVD in Women. Women. ’. s CV Risk is Often Misunderstood or Misdiagnosed. Gender Disparities in Screening, Diagnosis, and Treatment of Dyslipidemia. Optimizing . patient care. William Cromwell, MD, FAHA, FNLA. Chief Medical Officer – LipoScience, Inc.. Chief – Lipoprotein and Metabolic Disorders Institute. Adjunct Associate Professor – Wake Forest University School of Medicine. DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. common goal. a. common goal. “These guidelines are meant to define practices that meet the needs of patients in most circumstances and are not a replacement for clinical judgment. The ultimate decision about care of a particular patient must be made by the healthcare provider and patient in light of the circumstances presented by that patient. As a result, situations might arise in which deviations from these guidelines may be appropriate. These considerations notwithstanding, in caring for most patients, clinicians can employ the recommendations confidently to reduce the risks of atherosclerotic cardiovascular disease (ASCVD) events.”. Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016) G.B. John Mancini, MD, Steven Baker, MD, Jean Bergeron, MD, David Fitchett, MD, Purpose. Outline highlights from the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Review statin management in high risk patients. 2. ACC/AHA 2018: Overall Approach. Assess risk, determine management group. cross . the . spectrum . of . risk. : . Secondary . stroke . p. revention. . (N=488). Simvastatin. in Patients With Prior . Cerebrovascular. Disease: HPS. *29% RRR, . p. =0.001. Heart Protection Study Collaborative Group. . Quality Department Guidelines for Clinical Care Ambulatory Lipid TherapyGuideline TeamTeam LeaderAudrey LFan, MDGeneral MedicineTeam MembersJill NFenske, MDFamily MedicineVan Harrison, PhDMedical Educ Slide deck. The full text of the paper is available at. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31652-0/fulltext. . Rationale. Lipoprotein. (a) . is. an . established. . risk. How Will This Affect Practice in the Future?. Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA. Director, . Seinsheimer. Cardiovascular Health Program. Co-Director, Women’s Heart Care. President-Elect, Southeast Lipid Association (SELA).